APA (7th ed.) Citation

P, R., T, T., MJ, F., D, M., K, F., C, L., . . . M, S. (2026). Darolutamide versus abiraterone acetate-based triplets in patients with hormone-sensitive prostate cancer: Real-world, head-to-head comparison from the ARON-3 study. Minerva urology and nephrology. https://doi.org/10.23736/S2724-6051.26.06453-0

Chicago Style (17th ed.) Citation

P, Rescigno, et al. "Darolutamide Versus Abiraterone Acetate-based Triplets in Patients with Hormone-sensitive Prostate Cancer: Real-world, Head-to-head Comparison from the ARON-3 Study." Minerva Urology and Nephrology 2026. https://doi.org/10.23736/S2724-6051.26.06453-0.

MLA (9th ed.) Citation

P, Rescigno, et al. "Darolutamide Versus Abiraterone Acetate-based Triplets in Patients with Hormone-sensitive Prostate Cancer: Real-world, Head-to-head Comparison from the ARON-3 Study." Minerva Urology and Nephrology, 2026, https://doi.org/10.23736/S2724-6051.26.06453-0.